Join the BioNap Email List!

Friday, August 11, 2017

The BioNap Weekly Newsletter!

Hi Everyone!

I decided to publish my Newsletter on the web this week. If you're new to the Weekly BioNap Round-Up, welcome! Below is a taste of what you get each week by subscribing to my Newsletter completely free! Just enter your email in the box above.

If you are a subscriber to Bio5C, all the links and reports below are live. If you're not a Bio5C sub, you're missing out on great content! It's 100% independent biopharma research on ~100 small-cap names, updated in real-time for only $50 a month ($500 per year)! Join Bio5C and see! We also have an active Chat Board where I post these summaries live throughout the week and exchange ideas with subs. I plan to start using my Chat board more (and Twitter less) for commentary on Bio5C stocks, so join today and start investing the Bio5C way!

Now onto the research!

Wednesday, August 2, 2017

BriaCell Expands Pipeline Through Acquisition of Sapientia

Last week, BriaCell Therapeutics Corp. (TSVX: BCT) (BCTXF) announced a major expansion of the company's pipeline through the acquisition of privately-held Sapientia Pharmaceuticals, Inc. Through Sapientia, a biotechnology company based in Havertown, PA, BriaCell gains control of a pipeline of novel small molecules with solid intellectual property for the potential treatment of several cancers and fibrotic diseases. The acquisition expands the company's pipeline beyond BriaVax, a therapeutic cancer vaccine currently in a Phase 1/2 clinical trial for patients with advanced breast cancer.

Wednesday, July 19, 2017

BriaCell Clinical Update Shows Progress With Breast Cancer Program

BriaCell Therapeutics Corp. (TSXV: BCT) (OTC: BCTXF) continues to enroll patients in its Phase 1/2a clinical trial of BriaVax™ for the treatment of advanced breast cancer. The third patient enrolled earlier this week, making it three patients over the past three months. Management is expecting that pace to accelerate in the coming weeks, and now believes that the first ten patients will enroll by the end of September 2017. An interim data analysis of these first ten patients should be available during the first quarter 2018, setting up a nice potential catalyst for the shares.

Reporting data on BriaVax in patients with advanced metastatic breast cancer will be an important milestone for the company and represents many years of hard work by management to get BriaVax back into human clinical trials. I think BriaVax has tremendous potential as a targeted immunotherapy, so I'm excited to see the company moving forward and a nice catalyst on the horizon.